Literature DB >> 19275508

Concurrent chemotherapy and radiotherapy for head and neck cancer.

Ryan J Burri1, Nancy Y Lee.   

Abstract

Head and neck cancer is best managed in a multidisciplinary setting. Surgery, radiation therapy, chemotherapy and, more recently, biologic therapy are often employed in various combinations in an attempt to eradicate both clinically apparent and occult disease. The goals of treatment include maximizing tumor control while maintaining function and quality of life. Most patients present with locally advanced disease, and multimodality organ-conserving therapy is often employed for these patients based on the results of multiple Phase III clinical trials. This article focuses on the rationale and evidence supporting the use of concurrent chemotherapy and radiation therapy in the management of locally advanced head and neck cancers.

Entities:  

Mesh:

Year:  2009        PMID: 19275508     DOI: 10.1586/14737140.9.3.293

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  6 in total

Review 1.  Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.

Authors:  James E Frampton
Journal:  Drugs       Date:  2010-10-22       Impact factor: 9.546

2.  High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma.

Authors:  Mei-Kim Ang; Mihir R Patel; Xiao-Ying Yin; Sneha Sundaram; Karen Fritchie; Ni Zhao; Yufeng Liu; Alex J Freemerman; Matthew D Wilkerson; Vonn Walter; Mark C Weissler; William W Shockley; Marion E Couch; Adam M Zanation; Trevor Hackman; Bhishamjit S Chera; Stephen L Harris; C Ryan Miller; Leigh B Thorne; Michele C Hayward; William K Funkhouser; Andrew F Olshan; Carol G Shores; Liza Makowski; D Neil Hayes
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

3.  [New aspects of primary radiochemotherapy in head and neck cancer. Highlights from the 2011 ASCO Congress].

Authors:  S Laban; C J Wang; R Knecht; S Tribius; A Münscher
Journal:  HNO       Date:  2012-05       Impact factor: 1.284

4.  Association of anti-apoptotic Mcl-1L isoform expression with radioresistance of oral squamous carcinoma cells.

Authors:  Vinayak C Palve; Tanuja R Teni
Journal:  Radiat Oncol       Date:  2012-08-08       Impact factor: 3.481

5.  Heat generation and transfer behaviors of ti-coated carbon steel rod adaptable for ablation therapy of oral cancer.

Authors:  Takashi Naohara; Hiromichi Aono; Tsunehiro Maehara; Hideyuki Hirazawa; Shinya Matsutomo; Yuji Watanabe
Journal:  J Funct Biomater       Date:  2013-02-18

6.  Initial evidence for Sec62 as a prognostic marker in advanced head and neck squamous cell carcinoma.

Authors:  Silke Wemmert; Yasmin Lindner; Johannes Linxweiler; Stefan Wagenpfeil; Rainer Bohle; Marcus Niewald; Bernhard Schick
Journal:  Oncol Lett       Date:  2016-01-20       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.